PT2861573T - Derivados de oxatiazina como agentes antibacterianos e anticancerígeno - Google Patents
Derivados de oxatiazina como agentes antibacterianos e anticancerígenoInfo
- Publication number
- PT2861573T PT2861573T PT137341624T PT13734162T PT2861573T PT 2861573 T PT2861573 T PT 2861573T PT 137341624 T PT137341624 T PT 137341624T PT 13734162 T PT13734162 T PT 13734162T PT 2861573 T PT2861573 T PT 2861573T
- Authority
- PT
- Portugal
- Prior art keywords
- antibacterial
- anticancer agents
- oxathiazine
- derivatives
- oxathiazine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/10—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms two oxygen atoms and one sulfur atom, e.g. cyclic sulfates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661092P | 2012-06-18 | 2012-06-18 | |
| US201261694452P | 2012-08-29 | 2012-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2861573T true PT2861573T (pt) | 2017-11-14 |
Family
ID=48746589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137341624T PT2861573T (pt) | 2012-06-18 | 2013-06-17 | Derivados de oxatiazina como agentes antibacterianos e anticancerígeno |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9241943B2 (pt) |
| EP (1) | EP2861573B1 (pt) |
| DK (1) | DK2861573T3 (pt) |
| ES (1) | ES2644870T3 (pt) |
| HU (1) | HUE034822T2 (pt) |
| PL (1) | PL2861573T3 (pt) |
| PT (1) | PT2861573T (pt) |
| WO (1) | WO2013190355A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2644870T3 (es) * | 2012-06-18 | 2017-11-30 | Geistlich Pharma Ag | Derivados de oxatiazina como agentes antibacterianos y anticancerígenos |
| US10392355B2 (en) * | 2014-12-19 | 2019-08-27 | Geistlich Pharma Ag | Processes for preparing oxathiazin-like compounds |
| US11591302B2 (en) | 2014-12-19 | 2023-02-28 | Geistlich Pharm A Ag | Processes for preparing oxathiazin-like compounds |
| US11541061B2 (en) | 2016-01-11 | 2023-01-03 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
| ES2945712T3 (es) * | 2016-03-18 | 2023-07-06 | Geistlich Pharma Ag | Método de tratamiento de cáncer de mama triple negativo |
| US10544114B2 (en) | 2016-04-07 | 2020-01-28 | Geistlich Pharma Ag | Process for preparing oxathiazin-like compounds |
| ES2853999T3 (es) * | 2016-11-14 | 2021-09-20 | Byondis Bv | Proceso para la preparación de alpha, omega-diamino alcanos mono-protegidos |
| JP2021535173A (ja) * | 2018-08-28 | 2021-12-16 | コーメディクス・インコーポレーテッド | 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物 |
| WO2020234830A1 (en) * | 2019-05-22 | 2020-11-26 | Geistlich Pharma Ag | Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release |
| EP4330238A1 (en) * | 2021-04-29 | 2024-03-06 | Geistlich Pharma AG | Antimicrobial and anticancer agents |
| WO2024028846A1 (en) * | 2022-08-05 | 2024-02-08 | Geistlich Pharma Ag | Combination therapy for treating cancers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1160443B (de) * | 1961-11-30 | 1964-01-02 | Hoechst Ag | Verfahren zur Herstellung von Tetrahydro-oxathiazin-dioxyden |
| DE1234988B (de) * | 1964-11-28 | 1967-02-23 | Bayer Ag | Verfahren zur Herstellung von Copolymerisaten des Trioxans |
| GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
| US6117868A (en) * | 1998-09-16 | 2000-09-12 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Treatment of gastrointestinal ulcers or gastritis caused by microbial infection |
| ES2531547T3 (es) * | 1999-12-06 | 2015-03-17 | Geistlich Pharma Ag | Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores |
| ES2644870T3 (es) * | 2012-06-18 | 2017-11-30 | Geistlich Pharma Ag | Derivados de oxatiazina como agentes antibacterianos y anticancerígenos |
-
2013
- 2013-06-17 ES ES13734162.4T patent/ES2644870T3/es active Active
- 2013-06-17 EP EP13734162.4A patent/EP2861573B1/en active Active
- 2013-06-17 PL PL13734162T patent/PL2861573T3/pl unknown
- 2013-06-17 PT PT137341624T patent/PT2861573T/pt unknown
- 2013-06-17 DK DK13734162.4T patent/DK2861573T3/da active
- 2013-06-17 US US14/409,352 patent/US9241943B2/en active Active
- 2013-06-17 HU HUE13734162A patent/HUE034822T2/en unknown
- 2013-06-17 WO PCT/IB2013/001261 patent/WO2013190355A1/en active Application Filing
-
2015
- 2015-12-03 US US14/958,225 patent/US9624187B2/en active Active
-
2017
- 2017-03-29 US US15/472,550 patent/US9844555B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160159759A1 (en) | 2016-06-09 |
| DK2861573T3 (da) | 2017-11-13 |
| US9844555B2 (en) | 2017-12-19 |
| HUE034822T2 (en) | 2018-03-28 |
| US20150182534A1 (en) | 2015-07-02 |
| EP2861573A1 (en) | 2015-04-22 |
| US9241943B2 (en) | 2016-01-26 |
| US9624187B2 (en) | 2017-04-18 |
| WO2013190355A1 (en) | 2013-12-27 |
| US20170196876A1 (en) | 2017-07-13 |
| ES2644870T3 (es) | 2017-11-30 |
| EP2861573B1 (en) | 2017-08-30 |
| PL2861573T3 (pl) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201506880B (en) | Quinolines derivatives as novel anticancer agents | |
| HK1203927A1 (en) | Heterocyclic compounds and uses as anticancer agents | |
| IL233863A0 (en) | Pyridine derivatives, preparations containing them and their uses | |
| PL2861573T3 (pl) | Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe | |
| GB201304967D0 (en) | . | |
| IL237068A (en) | 1,3-dioxanomorphides and 1,3-dioxanocodides | |
| GB201204183D0 (en) | . | |
| IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
| EP3016716A4 (en) | Anticancer combinations | |
| EP2822558A4 (en) | PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY | |
| EP2873701A4 (en) | ORGANIC-INORGANIC COMPLEX, AND COMPOSITION FOR THE FORMATION OF SAID COMPLEX | |
| HK1198833A1 (en) | N-acylpeptide derivatives and their uses n- | |
| HK1203811A1 (en) | Anticancer agent | |
| HK1207317A1 (en) | Substituted 1,6-naphthyridines 16- | |
| HK1215031A1 (zh) | 抗微生物劑 | |
| IL238452A0 (en) | History of new modified 4,1-dithienes and their use as fungicides | |
| EP2864362A4 (en) | ANTICANCER TREATMENT | |
| EP2903979A4 (en) | Novel compounds, their preparation and use | |
| IL233682A0 (en) | Modified phenylazole derivatives, preparations containing them and their uses | |
| EP2837387A4 (en) | ANTICANCER AGENT | |
| HK1200821A1 (en) | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators gpbar1 12-16-- | |
| GB201603522D0 (en) | Pyrazolochalcones as potential anticancer agents | |
| EP2915536A4 (en) | ANTICROBREAM AND COMBINATION WITH THE ANTICREMENT | |
| GB201214551D0 (en) | Anticancer treatment | |
| GB201218175D0 (en) | Anticancer treatments |